文献速递临床试验与 GCP

重症Covid-19患者治疗剂量肝素抗凝的随机试验

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
PubMed 文献 · N Engl J Med · 2021-08-04

本研究为开放标签、适应性、多平台随机临床试验,纳入重症Covid-19患者,比较治疗剂量肝素抗凝与常规药物血栓预防。主要终点为无器官支持天数,因预设无效标准而提前终止;两组无器官支持天数中位数分别为1天和4天,调整比例优势比为0.83(95%可信区间0.67-1.03),存活出院率相似。

要点

  • 治疗剂量肝素未增加重症Covid-19患者存活出院概率。
  • 治疗剂量肝素未增加无心血管或呼吸器官支持天数。
  • 治疗剂量肝素大出血发生率为3.8%,常规预防为2.3%。

核心结论

  • 在重症Covid-19患者中,初始治疗剂量肝素抗凝未比常规药物血栓预防带来更高的存活出院概率或无器官支持天数。

研究设计与样本

  • 开放标签、适应性、多平台随机临床试验,因治疗剂量抗凝达到预设无效标准而提前终止。
  • 主要终点数据可获取的患者共1098例,其中治疗剂量肝素组534例,常规预防组564例。

主要发现

  • 无器官支持天数中位数治疗剂量组为1天(四分位距-1至16),常规预防组为4天(四分位距-1至16)。
  • 调整比例优势比为0.83(95%可信区间0.67至1.03),无效性后验概率(定义为优势比<1.2)为99.9%。
  • 存活出院率治疗剂量组为62.7%,常规预防组为64.5%,调整优势比为0.84(95%可信区间0.64至1.11)。
  • 大出血发生率治疗剂量组为3.8%,常规预防组为2.3%。

临床怎么用

  • 重症Covid-19患者不应常规采用治疗剂量肝素抗凝,仍按当地常规进行药物血栓预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS: In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. RESULTS: The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. CONCLUSIONS: In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707, NCT04505774, NCT04359277, and NCT04372589.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021. PMID: 34351722. doi:10.1056/NEJMoa2103417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。